Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
122
datasets available to search
ShareScore release 0.9.0
Dataset results
122 results for “treatment costs”
Wastewater Treatment Unit Processes Datasets: Pollutant removal efficiencies, evaluation criteria and cost estimations
<p>This dataset provides data on typical pollutant removal efficiencies, evaluation critera and cost estimation for 37 common wastewater treatment unit processes. The data is based on literature research, expert workshops and estimations.</p> <p>The following files are available:</p> <ul> <li>Pollutant removal efficiencies, evaluation criteria and cost estimations for wastewater treatment unit processes (dataset) - Microsoft Excel:<br> Database of pollutant removal efficiencies for 11 paramameters, cost estimation and evaluation criteria.</li> <li>Pollutant Removal Efficiencies for Wastewater Treatment Unit Processes (Dataset) - pdf</li> <li>Evaluation Criteria for Wastewater Treatment Unit Processes (Dataset) - pdf</li> <li>Cost Estimation for Wastewater Treatment Unit Processes (Dataset) - pdf</li> </ul> <p> </p> <p> </p>
The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults
<p>Dataset used for the study titled "A relative cost of control analyses of once weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults"</p>
Code to find the cost-effective treatments to stop a propagating front
<p>Invasive species propagation is a common phenomenon, and a major question is how humans would stop its propagation in the most cost-effective manner. This package includes software and simulation results to find the optimal shape of the suppression function under certain conditions.</p> <p>This package accompanies the paper "Optimizing the use of suppression zones for containment of invasive species" by Adam Lampert and Andrew Liebhold. In particular, it includes the complete code for generating Figs. 2-4 in the paper. The file front_complete_code.zip includes the entire code. The file simulation_results.zip includes the results.</p>
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
ClinicalTrials.gov study NCT00303186. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Cost-effectiveness of leveraging existing HIV primary health systems and community health workers for hypertension screening and treatment in Africa: An individual-based modelling study
Open the record for dataset details and reuse information.
Code to find the cost-effective treatments to stop a propagating front
Open the record for dataset details and reuse information.
Half-Dose Fulvestrant plus Anastrozole as a First-Line Treatment for Hormone Receptor-Positive Metastatic Breast Cancer: A Cost-Effectiveness Analysis
Abstract Objective The S0226 trial demonstrated that the combination of half-dose fulvestrant (FUL) and anastrozole (ANA) (F&A) caused a significant improvement in overall survival (OS) versus ANA monotherapy for first-line treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer (PMW-MBC[HR+]). The objective of this study was to evaluate the cost-effectiveness of F&A in the first-line treatment for PMW-MBC(HR+) in China. Design We constructed a Markov model over a life-time horizon. The clinical outcomes and utility data were obtained from published literature. Cost data were obtained from official Chinese websites. Sensitivity analyses were performed to test result uncertainty. Setting Chinese health care system perspective. Population A hypothetical cohort of adult patients presenting with PMW-MBC(HR+). Interventions F&A compared with full-dose FUL and ANA monotherapy. Main outcome measures The main outcome of this study was the incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALY). Results ANA was estimated to have the lowest cost and minimum life years (LYs). The ICER of F&A versus ANA was $15,665.891/QALY with incremental cost and QALY of $12,401.120 and 0.792, respectively, which was less than the willingness-to-pay (WTP) of $29,383/QALY. Compared with F&A, FUL yielded a higher cost and a shorter lifetime; hence, it was identified as a dominated strategy. The univariate sensitivity analysis indicated the price of FUL was the most influential factor in our study. The probability that F&A was cost-effective at a threshold of $29,383/QALY in China was 86.5%. Conclusion F&A is a cost-effective alternative to FUL and ANA monotherapy for the first-line treatment of PMW-MBC(HR+) in China. F&A is a promising first-line treatment for PMW-MBC(HR+), and more research is needed to evaluate the economy of using F&A in other countries.
Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial
<p><b>Objectives</b> Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China.</p> <p><b>Design</b> A combined decision tree and Markov model with three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with RAS wt mCRC. The health outcomes and utility scores were derived from the TAILOR trial and previously published sources, respectively. Costs were calculated with reference to the Chinese societal perspective. A lifetime horizon was used. Univariate and probabilistic sensitivity analyses were carried out to test the robustness of the model results.</p> <p><b>Participants</b> The included patients were newly diagnosed Chinese patients with fully RAS wt mCRC. <b>Interventions</b> Either cetuximab plus FOLFOX-4 or FOLFOX-4 alone as a first-line treatment.</p> <p><b>Main outcome measures</b> The primary outcomes are costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs).</p> <p><b>Results</b> Baseline analysis showed that the addition of cetuximab increased the QALYs by 0.383, while an increase of $62,947 was observed in relation to FOLFOX-4 chemotherapy. This led to an incremental cost-effectiveness ratio (ICER) of $164,044/QALY. Sensitivity analysis showed that across the wide variation in parameters, the ICER exceeded the willingness-to-pay threshold of $28,106/QALY, which was three times the per capita GDP in China.</p> <p><b>Conclusions</b> Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first line treatment of patients with RAS wt mCRC in China.</p>
Data from: Diagnostic pathways and direct medical costs incurred by new adult pulmonary tuberculosis patients prior to anti-tuberculosis treatment – Tamil Nadu, India
Background: Tuberculosis (TB) patients face substantial delays prior to treatment initiation, and out of pocket (OOP) expenditures often surpass the economic productivity of the household. We evaluated the pre-diagnostic cost and health seeking behaviour of new adult pulmonary TB patients registered at Primary Health Centres (PHCs) in Vellore district, Tamil Nadu, India. Methods: This descriptive study, part of a randomised controlled trial conducted in three rural Tuberculosis Units from Dec 2012 to Dec 2015, collected data on number of health facilities, dates of visits prior to the initiation of anti-tuberculosis treatment, and direct OOP medical costs associated with TB diagnosis. Logistic regression analysis examined the factors associated with delays in treatment initiation and OOP expenditures. Results: Of 880 TB patients interviewed, 34.7% presented to public health facilities and 65% patients sought private health facilities as their first point of care. The average monthly individual income was $77.79 (SD 57.14). About 69% incurred some pre-treatment costs at an average of $39.74. Overall, patients experienced a median of 6 days (3-11 IQR) of time to treatment initiation and 21 days (10-30 IQR) of health systems delay. Age ≤ 40 years (aOR: 1.73; CI: 1.22 - 2.44), diabetes (aOR: 1.63; CI: 1.08 - 2.44) and first visit to a private health facility (aOR: 17.2; CI: 11.1 - 26.4) were associated with higher direct OOP medical costs, while age ≤ 40 years (aOR: 0.64; CI: 0.48 - 0.85) and first visit to private health facility (aOR: 1.79, CI: 1.34 - 2.39) were associated with health systems delay. Conclusion: The majority of rural TB patients registering at PHCs visited private health facilities first and incurred substantial direct OOP medical costs and delays prior to diagnosis and anti-tuberculosis treatment initiation. This study highlights the need for PHCs to be made as the preferred choice for first point of contact, to combat TB more efficiently.
A cost-effectiveness analysis of second-generation antihistamine 1 receptor blockers and Japanese kampo shoseiryuto for treatment of perennial allergic rhinitis in outpatient settings in Japan
<p><strong><span>Background: </span></strong><span>Perennial allergic rhinitis (PAR) is common in Japan. Second-generation antihistamines (SGAs) are used commonly </span><span>for its</span><span> treatment, but it remains unclear which SGA is the most cost-effective. Additionally, the pharmacoeconomics of Japanese kampo shoseiryuto, which has been traditionally prescribed to treat PAR in Japan, remain poorly understood.</span></p> <p><strong><span>Objectives: </span></strong><span>This study aimed to investigate the effectiveness of various SGAs and shoseiryuto for the treatment of PAR in Japanese outpatients, from the healthcare payer's perspective, using a base-case analysis.</span></p> <p><strong><span>Methods: </span></strong><span>The current study entailed identification of the most cost-effective of the six SGAs (</span><span>bepotastine 10 mg, cetirizine 10 mg, ebastine 10 mg, </span><span>epinastine 20</span><span> mg, loratadine 10 mg, and olopatadine 5 mg) and shoseiryuto, whose clinical effectiveness were evaluated using the overall improvement rate. </span><span>T</span><span>he time horizon</span><span> was 14 days. Costs were identified based on the Medical Fee Index in 2020.</span></p> <p><strong><span>Key findings: </span></strong><span>Overall, bepotastine 10 mg, cetirizine 10 mg, </span><span>ebastine </span><span>10 mg, and loratadine 10 mg were found to be cost-effective. Shoseiryuto was less cost-effective than ebastine 10 mg (dominated). Ebastine 10 mg was found to be the most cost-effective based on deterministic and probabilistic sensitivity analyses.</span></p> <p><strong><span>Conclusions: </span></strong><span>Ebastine 10 mg was found to be the most cost-effective treatment strategy for PAR among the agents evaluated in this study</span><span>. This insight might help </span><span>in creating an appropriate formulary for the treatment of PAR in hospitals and communities.</span></p>
Dataset for a systematic review on the costs and cost-effectiveness of treatment setting for children with wasting, oedema and growth failure/faltering
<p>This dataset contains data extraction tables, and results graphs, figures and other visualizations from the systematic review on the costs and cost-effectiveness of treatment setting for children with wasting, oedema and growth failure/faltering.</p>
The (Cost-)Effectiveness of Generalist Versus Specialist Treatment for Severe Personality Disorders'
ClinicalTrials.gov study NCT06789380. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Implementation, Efficacy and Costs of Inpatient Equivalent Home-Treatment in German Mental Health Care
ClinicalTrials.gov study NCT04745507. IPD Sharing: Not stated. Countries: 1. Publications: 7.
Study on Costs and Safety of Early Conversion From Intravenous to Oral Antibiotic Treatment in Patients With Severe Community-Acquired Pneumonia
ClinicalTrials.gov study NCT00273676. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Procalcitonin-guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients
ClinicalTrials.gov study NCT02202941. IPD Sharing: Not stated. Countries: 1. Publications: 1.
To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
ClinicalTrials.gov study NCT00007774. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cost-effectiveness of Extracorporeal Life Support Treatment
ClinicalTrials.gov study NCT02837419. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) i
ClinicalTrials.gov study NCT01331694. IPD Sharing: Not stated. Countries: 0. Publications: 1.
The Effectiveness and Cost-effectiveness of Motion Style Acupuncture Treatment (MSAT) for Acute Neck Pain: A Multi-center Randomized Controlled Trial
ClinicalTrials.gov study NCT04539184. IPD Sharing: NO. Countries: 1. Publications: 2.
Comparison of Effectiveness and Costs of Post-diagnosis Treatment in Dementia
ClinicalTrials.gov study NCT00554047. IPD Sharing: Not stated. Countries: 1. Publications: 3.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.